

1. A contraceptive and/or HRT kit comprising a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15.  
5
2. A kit according to claim 1 wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.  
10
3. A kit according to claim 1 or 2 further comprising a contraceptively and/or therapeutically effective amount of an androgen ester.
4. A kit according to claim 3 wherein the androgen ester is MENT undecanoate.  
15
5. A kit according to claim 4 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-400 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 25-200 mg.  
20
6. A kit according to claim 5 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-200 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50-100 mg.  
25
7. A kit according to claim 6 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 100 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50 mg.  
30
8. A kit according to claim 1 or 2 further comprising a contraceptively and/or therapeutically effective amount of an estrogen.

9. A use of a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15 for the preparation of a medicament for contraception and/or HRT.
- 5 10. A use according to claim 9 wherein the ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.
- 10 11. A use of a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15 in conjunction with a contraceptively and/or therapeutically effective amount of a long-acting androgen ester for the preparation of a medicament for male contraception and/or male HRT.
- 15 12. A use according to claim 11 wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate and the androgen ester is MENT undecanoate.
- 20 13. A use according to claim 12 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-400 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 25-200 mg.
- 25 14. A use according to claim 13 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-200 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50-100 mg.
- 30 15. A use according to claim 14 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 100 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50 mg.
- 35 16. A use of a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15 in conjunction with a contraceptively and/or therapeutically effective amount

of an estrogen for the preparation of a medicament for female contraception and/or female HRT.

- 5 17. A use according to claim 16 wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.
- 10 18. A method of contraception and/or HRT comprising administering to a subject a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15.
- 15 19. A method according to claim 18 wherein the ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.
- 20 20. A method according to claim 18 wherein a contraceptively and/or therapeutically effective amount of a long-acting androgen ester is administered in conjunction with the etonogestrel ester.
- 25 21. A method according to claim 20 wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate and the androgen ester is MENT undecanoate.
- 30 22. A method according to claim 21 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-400 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 25-200 mg.
- 35 23. A method according to claim 22 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-200 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50-100 mg.
24. A method according to claim 23 wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 100 mg and the

contraceptively and/or therapeutically effective amount of etonogestrel ester is 50 mg.

- 5 25. A method according to claim 18 or 19 wherein a contraceptively and/or therapeutically effective amount of an estrogen is administered in conjunction with the etonogestrel ester.
- 10 26. A use of a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15 for the preparation of a medicament for the treatment and/or prevention of a female gynaecological disorder.
- 15 27. A use according to claim 26 wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.
- 20 28. A use according to claim 26 or 27 wherein the female gynaecological disorder is selected from the group consisting of endometriosis, menorrhagia, meno-metrorrhagia, pre-menstrual syndrome and dysmenorrhoea.
- 25 29. A method of treating and/or preventing a female gynaecological disorder comprising administering to a female subject a therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15 effective to treat and/or prevent the disorder.
- 30 30. A method according to claim 29 wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.
- 35 31. A method according to claim 29 or 30 wherein the female gynaecological disorder is selected from the group consisting of endometriosis, menorrhagia, meno-metrorrhagia, pre-menstrual syndrome and dysmenorrhoea.